TY - JOUR T1 - Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup>C-RO-963, <sup>11</sup>C-RO-643, and <sup>18</sup>F-RO-948, in Healthy Controls and in Alzheimer Subjects JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1869 LP - 1876 DO - 10.2967/jnumed.118.209916 VL - 59 IS - 12 AU - Dean F. Wong AU - Robert A. Comley AU - Hiroto Kuwabara AU - Paul B. Rosenberg AU - Susan M. Resnick AU - Susanne Ostrowitzki AU - Cristina Vozzi AU - Frank Boess AU - Esther Oh AU - Constantine G. Lyketsos AU - Michael Honer AU - Luca Gobbi AU - Gregory Klein AU - Noble George AU - Lorena Gapasin AU - Kelly Kitzmiller AU - Josh Roberts AU - Jeff Sevigny AU - Ayon Nandi AU - James Brasic AU - Chakradhar Mishra AU - Madhav Thambisetty AU - Abhay Moghekar AU - Anil Mathur AU - Marilyn Albert AU - Robert F. Dannals AU - Edilio Borroni Y1 - 2018/12/01 UR - http://jnm.snmjournals.org/content/59/12/1869.abstract N2 - 11C-RO-963, 11C-RO-643, and 18F-RO-948 (previously referred to as 11C-RO6924963, 11C-RO6931643, and 18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of 11C-RO-963, 11C-RO-643, or 18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with 18F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated 18F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with 18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for 11C-RO-963, 1.5 for 11C-RO-643, and 3.5 for 18F-RO-948. Over all brain regions and subjects, the trend was for 18F-RO-948 to have the highest SUVpeak, followed by 11C-RO-963 and then 11C-RO-643. Regional analysis of SUV ratio and total distribution volume for 11C-RO-643 and 18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that 11C-RO-643 had lower brain entry than either 11C-RO-963 or 18F-RO-948 and that 18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on 18F-RO-948. Both voxelwise and region-based analysis of 18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) = 45, P &lt; 10−5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P &lt; 0.001, cluster size &gt; 50). Conclusion: 18F-RO-948 demonstrates characteristics superior to 11C-RO-643 and 11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of 18F-RO-948 compare favorably with other existing tau PET tracers. ER -